Recent Security Class Actions

Akebia Therapeutics Inc. Common Stock (NASDAQ: AKBA)

Company Name:Akebia Therapeutics Inc. Common Stock
Stock Symbol:NASDAQ: AKBA
Class Period Start:06/28/2018
Class Period End (inclusive):09/02/2020

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) vadadustat was not as safe in treating NDD-CKD patients with anemia as Defendants had represented; (ii) as a result, Defendants overstated the PRO2TECT Program’s clinical prospects; (iii) accordingly, Defendants also overstated vadadustat’s overall commercial and regulatory prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.